Published in Cancer on June 15, 1980
A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg (1982) 2.09
A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09
Recent advances in the care of the patient with malignant melanoma. Ann Surg (1997) 1.92
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg (1988) 1.19
Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg (1982) 1.15
Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98
Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol (2011) 0.94
Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses. Anticancer Res (2014) 0.93
Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology. Virchows Arch (2009) 0.93
Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg (1984) 0.93
Cutaneous malignant melanoma in Scotland. Br J Cancer (1982) 0.93
Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met. J Invest Dermatol (2010) 0.92
Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol (2013) 0.91
Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res (2011) 0.90
Poor prognosis for malignant melanoma in Northern Ireland: a multivariate analysis. Br J Cancer (1991) 0.86
Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiol Biomarkers Prev (2013) 0.82
Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett (2010) 0.81
ACP best practice no 162. The histological reporting of melanoma. Association of Clinical Pathologists. J Clin Pathol (2000) 0.81
Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group. Br J Cancer (1996) 0.78
Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis). Trans Am Ophthalmol Soc (2012) 0.78
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor? World J Surg (2009) 0.77
Intraoperative identification of sentinel lymph node in patients with malignant melanoma. Br J Cancer (1997) 0.77
Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer (2011) 0.76
High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi. Int J Clin Exp Pathol (2015) 0.75
Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol (2014) 0.75
Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother (2015) 0.75
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol (1981) 8.17
Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med (1977) 5.02
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med (1996) 4.28
A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol (1983) 3.80
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74
A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg (1978) 2.94
Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics (2001) 2.91
Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics (1980) 2.70
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery (1979) 2.65
Characterization of HNK-1+ (Leu-7) human lymphocytes. I. Two distinct phenotypes of human NK cells with different cytotoxic capability. J Immunol (1982) 2.63
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer (1979) 2.41
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med (1982) 2.35
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg (1982) 2.09
A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol (1985) 2.03
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med (1988) 1.98
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol (1998) 1.92
Recent advances in the care of the patient with malignant melanoma. Ann Surg (1997) 1.92
Conventional TRAM flap versus free microsurgical TRAM flap for immediate breast reconstruction. Plast Reconstr Surg (1989) 1.87
Herpes simplex encephalitis. Clinical Assessment. JAMA (1982) 1.83
Role of the pericyte in wound healing. An ultrastructural study. Exp Mol Pathol (1970) 1.78
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
A randomized trial to improve self-management practices of adults with asthma. Arch Intern Med (1990) 1.67
Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg (1982) 1.62
Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med (2001) 1.60
Suppressor cell function of human granular lymphocytes identified by the HNK-1 (Leu 7) monoclonal antibody. J Immunol (1983) 1.60
Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol (1998) 1.57
Foreign bodies in the appendix. Report of eight cases and review of the literature. Arch Surg (1971) 1.55
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Predictors of sun exposure in adolescents in a southeastern U.S. population. J Adolesc Health (1996) 1.50
The ultrastructure of medullary and scirrhous mammary duct carcinoma. Am J Pathol (1967) 1.50
Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis (1996) 1.50
Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res (1986) 1.50
Differentiation stages of human natural killer cells in lymphoid tissues from fetal to adult life. J Exp Med (1983) 1.48
Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol (1996) 1.48
A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol (1983) 1.46
Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol (1992) 1.45
A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg (1983) 1.45
Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol (1991) 1.42
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J (1996) 1.41
What is a surgical oncologist? Ann Surg Oncol (1994) 1.40
Prognostic histopathological factors in malignant melanoma. Pathology (1985) 1.39
How patient referral bias can confuse interpretation of clinical results: elective lymph node dissections at the Sydney Melanoma Unit. J Am Coll Surg (1995) 1.39
The needle biopsy should replace open excisional biopsy ... but will the surgeon's role in coordinating breast cancer treatment be diminished? Ann Surg Oncol (1995) 1.39
Think melanoma. South Med J (1993) 1.39
Characterization of HNK-1+ (Leu-7) human lymphocytes. II. Distinguishing phenotypic and functional properties of natural killer cells from activated NK-like cells. J Immunol (1982) 1.38
Isolation and partial characterization of the human homologue of Thy-1. J Exp Med (1980) 1.34
Surgery for abdominal metastases of cutaneous melanoma. World J Surg (2001) 1.33
Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973-1992. J Health Care Poor Underserved (1998) 1.31
Treatment of secondary hyperparathyroidism in patients with chronic renal failure by total parathyroidectomy and parathyroid autograft. Ann Surg (1981) 1.30
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Ultrastructure of a hemangiopericytoma and a glomus tumor. Cancer (1968) 1.29
Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med (1982) 1.27
Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases. Gastroenterology (1983) 1.26
Survival following locoregional recurrence after breast conservation therapy for cancer. Ann Surg (1990) 1.25
The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer (1985) 1.24
Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease. Gastroenterology (1984) 1.22
Ultrastructure of myoepithelial cells in human mammary gland tumors. Cancer (1968) 1.21